Table 2.
Effect of NBN 657del5 on prostate risk among studied groups, by genotype of the E185Q missense variant
| Variants present | Unselected prostate cancer cases |
Familial prostate cancer cases |
Control No. | ||||
|---|---|---|---|---|---|---|---|
| No. | OR (95% Cl) | p-value | No. | OR (95% Cl) | p-value | ||
| Effect of NBN 657del5 on cancer risk among carriers of GG genotype of E185Q | |||||||
| NBN 657del5–negative and GG genotype | 2,157 | 4.4 (2.4-8.0) | < 0.001 | 260 | 7.2 (3.1-16.3) | < 0.001 | 2,603 |
| NBN 657del5–positive and GG genotype | 50 | 10 | 14 | 14 | |||
| Effect of NBN 657del5 on cancer risk among carriers of GC/CC genotype of E185Q | |||||||
| NBN 657del5–negative and GC/CC genotype | 2,958 | 1.4 (0.8-2.4) | 0.382 | 359 | 2.3 (0.9-6.2) | 0.161 | 3,514 |
| NBN 657del5–positive and GC/CC genotype | 24 | 5 | 21 | ||||
OR, odds ratio; CI, confidence interval.